Drug
Levalbuterol Tartrate Hfa Mdi
Levalbuterol Tartrate Hfa Mdi: highest development phase Phase 3, developed by Sumitomo Pharma. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sumitomo Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Levalbuterol tartrate HFA MDI NCT00268723 | Phase 3 | Exercise-induced Bronchospasm |
| levalbuterol tartrate HFA MDI NCT00064389 | Phase 3 | Asthma |
Latest
No recent events.
Follow Levalbuterol Tartrate Hfa Mdi on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.